Annual General Meeting of Ypsomed approved all proposals

Press Releases Ypsomed Group

Burgdorf – At the Annual General Meeting of Ypsomed Holding AG (SIX: YPSN) held on 2 July 2025, the shareholders approved all proposals put forward by the Board of Directors. Marie-Pierre Zerr was newly elected to the Board of Directors. Gilbert Achermann, Paul Fonteyne,
Dr. Martin Münchbach, and Simon Michel were re-elected as Members of the Board, and Gilbert Achermann was confirmed as Chairman of the Board.

Lue lisää...

Globally first dual GCG/GLP-1 receptor agonist for the treatment of obesity launched in an Ypsomed autoinjector in China

Press Releases Ypsomed Group

Burgdorf – A new chapter in the treatment of obesity begins with the approval of the world's first dual GCG/GLP-1 receptor agonist drug delivered using an Ypsomed autoinjector in China. Innovent Biologics, Inc. (XHKG: 1801), a leading Chinese biopharmaceutical company, has received approval from the Chinese National Medical Products Administration (NMPA) for Mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of people with obesity, which is now launching in an YpsoMate 1.0 autoinjector variant.

Aiheita:
Platforms & Operational Excellence

Lue lisää...

Ypsomed opens production site in China

Press Releases Ypsomed Group

Burgdorf – On 26 June 2025, Ypsomed opened its first dedicated production site in China with a festive ceremony. The new facility, located in Changzhou’s high-tech industrial park near Shanghai, was completed in just 14 months and marks a further milestone in the company’s global growth strategy. 

Aiheita:
Platforms & Operational Excellence

Lue lisää...

mylife Loop to integrate Abbott’s future dual glucose-ketone sensor into their solution, combining mylife YpsoPump and mylife CamAPS FX, designed to improve the life of people living with diabetes

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and CamDiab announce their agreement to integrate mylife Loop automated insulin delivery (AID) system with Abbott’s next-generation dual glucose-ketone sensor, which is currently under development.

Aiheita:
Innovation & Digital Health

Lue lisää...

Ypsomed and CamDiab expand availability of mylife CamAPS FX on iOS

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN), in partnership with CamDiab, is continuing the successful rollout of the iOS version of the mylife CamAPS FX app, the controller component of the automated insulin delivery (AID) system, mylife Loop. In combination with the mylife YpsoPump insulin pump, this expansion enables more people with type 1 diabetes to discreetly manage their therapy using their personal iPhone. 

Aiheita:
Innovation & Digital Health

Lue lisää...